Keytruda (pembrolizumab) Receives Supplemental FDA Approval for Efficacy

The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab) on May 5, 2021. This approval, based on new efficacy data, expands the drug's label. The supplemental application was submitted by MERCK SHARP DOHME.

What this means

This supplemental approval for Keytruda (pembrolizumab) signifies an expansion of its approved uses, based on the FDA's review of new efficacy data. While the specific indication for this supplemental approval is not detailed in the provided information, such approvals typically mean that the drug is now cleared for use in an additional patient population or for a new disease indication, offering more treatment options for clinicians and patients. The approval underscores the ongoing development and evaluation of pembrolizumab's therapeutic potential.

Source

The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for supplemental application BLA 125514 S-97 for Keytruda (pembrolizumab) was posted on May 5, 2021, on accessdata.fda.gov.